PharmiWeb.com - Global Pharma News & Resources
15-Jul-2019

Psoriatic Arthritis Treatment Market Size Poised to Touch USD 17.8 Billion by 2026

The Global Psoriatic Arthritis Treatment Market Size projected to register USD 17.8 billion by 2026, registering at a CAGR growth of 9.9% over the forecast period 2019 to 2026.

The development is driven by the emergence of biological similarities, the launching of fresh products and the increasing consciousness by the customer. Among other drug classes in 2018, biologics produced the largest income. The growth segment is driven by demand for targeted therapy, enhanced safety amp; effectiveness profiles, expected launching of several pipeline applicants as well as powerful commercial performance of current goods. DMARDs will also retain a consistent development rate with the initial action of corticosteroids and the imminent release of JAK and TYK2 kinase inhibitors.

Led by a high level of healthcare expenditures, disease prevalence, the regional presence of important producers, and fast growth in consumer consciousness, in 2018 North America recorded the largest market share. Asia-Pacific is expected to show regional development in the forecast period as quickly as possible, driven by the growing trend of biosimiles, improvements in health infrastructure and higher disposable income.

The therapy of psoriatic arthritis (PSA), owing to biological and biosimilar therapies and the increasing use of new medicines, is continuously gaining great demand. Manufacturers have, in latest years, focused on strategic collaboration for the expansion of their companies in emerging markets and the creation of biological similar products. As a consequence of the introduction of biosimilars that undergo clinical trial programs the worldwide demand for psoriatic arthritis (PsA) therapy is increasing.

Download Free Sample Report at https://www.acumenresearchandconsulting.com/request-sample/1514

The psoriatic arthritis (Psa), which is anticipated to be caused by the growing incidence of psoriatic Arthritis (PsA) throughout the globe and by increased clinical research for the creation of new drugs for the therapy of psoriatic arthritis, is likely to grow steadily during the forecast period. An additional factor in economic growth, which also contribute to the growth of the Psoriatic Arthritis (PsA) industry, is the rise in financing for research and development.

Key Findings

In 2018, biodiversity accounted for over 50% of the market in psoriatic arthritis therapy. Infliximab, Risankizumab, guselkumab, bimekizumab, and tildrakizumab are expected to grow.

The marketplace is expected to increase. The development of DMARDs is probably positive for upadacitinib, filgotinib, and BMS-986 165 mdash; once it is launched.

Injectables represented in 2018 the biggest market share of PsA therapy among other paths.

In 2018, over half its income share was jointly recorded in North America and Europe and important growth is expected to take place in the coming years.

Key Players amp; Strategies

Some main players include Bristol-Myers Squibb Corporation, AbbVie Inc., Amgen Inc., Bausch Health Companies Inc. ; Johnson amp; Johnson Services Inc., AstraZenect plc, Celgene Corporation, Novartis International AG, and Pfizer Inc. University of Collaboration, Partnerships and Joint Ventures. Strategic projects, such as fusions and acquisitions, are becoming a heavy-handed market.

The main topics of this competitive landscape are continuous product development and successive launch of breakthrough products. In this industry, fresh products must have a major clinical benefit over current products, either in safety or efficacy, as the regulatory processes become more rigorous and competitive, or as the final outcome. This has resulted in many tests between important business goods, such as Humira and Remicade, and fresh goods or applicants for late-stage pipelines. Through comparative assessment of several parameters, these tests determine superior efficiency.

There is a high level of rivalry between players in the world market for Psoriatic Arthritis Treatments. The market is dominated by technologically sophisticated major players. The industry in Psoriatic Arthritis Treatment is capital-intensive and technological.

View Detail Information with Complete TOC at https://www.acumenresearchandconsulting.com/psoriatic-arthritis-treatment-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Psoriatic Arthritis Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Psoriatic Arthritis Treatment Market By Drug Class
1.2.2.1. Global Psoriatic Arthritis Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Psoriatic Arthritis Treatment Market Revenue Share By Drug Class in 2017
1.2.2.3. DMARD
1.2.2.4. NSAIDs
1.2.2.5. Biologics
1.2.2.6. Others
1.2.3. Psoriatic Arthritis Treatment Market By Product Type
1.2.3.1. Global Psoriatic Arthritis Treatment Market Revenue and Growth Rate Comparison By Product Type (2015-2026)
1.2.3.2. OTC
1.2.3.3. Prescriptions
1.2.4. Psoriatic Arthritis Treatment Market By Route of Administration
1.2.4.1. Global Psoriatic Arthritis Treatment Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.4.2. Oral
1.2.4.3. Topical
1.2.4.4. Injectable
1.2.5. Psoriatic Arthritis Treatment Market by Geography
1.2.5.1. Global Psoriatic Arthritis Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Psoriatic Arthritis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Psoriatic Arthritis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Psoriatic Arthritis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Psoriatic Arthritis Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Psoriatic Arthritis Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Psoriatic Arthritis Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Psoriatic Arthritis Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Drug Class of Global Psoriatic Arthritis Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Psoriatic Arthritis Treatment Major Manufacturers in 2017

CHAPTER 4. PSORIATIC ARTHRITIS TREATMENT MARKET BY DRUG CLASS

4.1. Global Psoriatic Arthritis Treatment Revenue By Drug Class
4.2. DMARD
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. NSAIDs
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Biologics
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Others
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. PSORIATIC ARTHRITIS TREATMENT MARKET BY PRODUCT TYPE

5.1. Global Psoriatic Arthritis Treatment Revenue By Product Type
5.2. OTC
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Prescriptions
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. PSORIATIC ARTHRITIS TREATMENT MARKET BY ROUTE OF ADMINISTRATION

6.1. Global Psoriatic Arthritis Treatment Revenue By Route of Administration
6.2. Oral
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Topical
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Injectable
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET BY COUNTRY

7.1. North America Psoriatic Arthritis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Psoriatic Arthritis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Psoriatic Arthritis Treatment Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET BY COUNTRY

8.1. Europe Psoriatic Arthritis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Psoriatic Arthritis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET BY COUNTRY

9.1. Asia-Pacific Psoriatic Arthritis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Psoriatic Arthritis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET BY COUNTRY

10.1. Latin America Psoriatic Arthritis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Psoriatic Arthritis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST PSORIATIC ARTHRITIS TREATMENT MARKET BY COUNTRY

11.1. Middle East Psoriatic Arthritis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Psoriatic Arthritis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET BY COUNTRY

12.1. Africa Psoriatic Arthritis Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Psoriatic Arthritis Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Product Type, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Bristol-Myers Squibb Corporation
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. AbbVie Inc.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Amgen Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Bausch Health Companies Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Johnson amp; Johnson Services Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. AstraZeneca plc
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Celgene Corporation
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Novartis International AG
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Pfizer Inc
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

Request for Customization: https://www.acumenresearchandconsulting.com/request-customization/1514

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1514

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 15-Jul-2019